Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment
Sponsored by Massimo Falconi
About this trial
Last updated 2 years ago
Study ID
FiReNEN
Status
Recruiting
Type
Observational
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 2 years ago
What is this trial about?
The aim of this study is to evaluate the financial toxicity reported by Italian patients
affected by GEP-NEN during the first year of treatment after diagnosis and its correlations
with patient-reported outcomes (PROs) and quality of life (QoL).
What are the participation requirements?
Inclusion Criteria
- ≥18 years of age
- New diagnosis of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN)
- Patients who are candidates for surgical and/or medical treatment [including somatostatin analogues (SAA), peptide recector radionuclide therapy (PRRT), target therapies (everolimus or sunitinib) and chemotherapy];
- Signed informed consent
Exclusion Criteria
- Age < 18 years
- Patients diagnosed with GEP-NEN who are candidates for a surveillance management.
- Patients diagnosed with GEP-NEN who are candidates for best supportive care and/or have a life expectancy < 6 months.
Locations
Location
Status
Recruiting